Status:
COMPLETED
A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy
Lead Sponsor:
Retina Institute of Hawaii
Conditions:
PDR
Eligibility:
All Genders
Up to 75 years
Phase:
PHASE1
Brief Summary
Primary objective of this trial will be to evaluate the safety and efficacy of intravitreal injections of Macugen (pegaptanib sodium) when given at least 7-14 days prior to vitrectomy in subjects with...
Eligibility Criteria
Inclusion
- Subjects of either gender aged 75 years or below diagnosed with tractional retinal detachment secondary to proliferative diabetic retinopathy.
Exclusion
- Subjects with vitreous hemorrhage obscuring the posterior pole will be excluded.
Key Trial Info
Start Date :
April 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01487070
Start Date
April 1 2011
End Date
July 1 2011
Last Update
December 7 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina Institute of Hawaii
Honolulu, Hawaii, United States, 96815